Translate
Regeneron Pharmaceuticals Inc
About
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Regeneron Reports First Quarter 2026 Financial and Operating Results
Apr 23 2026
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
Apr 23 2026
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
Apr 22 2026
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
Apr 13 2026
Telix and Regeneron Announce Strategic Radiopharma Collaboration
Recent Videos
Is Regeneron Pharmaceuticals Inc a Buy? | Full Deep Dive | REGN Analysis | StokTok
Apr 30, 2026
Regeneron Pharmaceuticals First Quarter 2026 Financial Results
Apr 30, 2026
Regeneron Valuation | The $1.2B Catalyst the Market Missed
Apr 29, 2026
Regeneron's Unlikely Rise: From Flopped Drug to Cancer Cure
Apr 29, 2026
Financials
Revenue
$14.34 B
Market Cap
$80.54 B
P/E Ratio
18.38
EPS
41.44
Dividend Yield
0.45%